135 related articles for article (PubMed ID: 37898348)
21. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
[TBL] [Abstract][Full Text] [Related]
22. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
23. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
[TBL] [Abstract][Full Text] [Related]
24. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
25. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
26. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P; Sonneveld MJ; Zoutendijk R; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Reijnders JG; Oo Y; Petersen J; van Bömmel F; de Knegt RJ; Santantonio T; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen B; Janssen HL;
Gut; 2015 Aug; 64(8):1289-95. PubMed ID: 25011935
[TBL] [Abstract][Full Text] [Related]
27. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
28. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study.
Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H
J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
[TBL] [Abstract][Full Text] [Related]
30. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
Kim SU; Seo YS; Lee HA; Kim MN; Kim EH; Kim HY; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):693-699.e1. PubMed ID: 31252188
[TBL] [Abstract][Full Text] [Related]
31. Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.
Oh JH; Lee HW; Sinn DH; Park JY; Kim BK; Kim SU; Kim DY; Ahn SH; Kang W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Paik YH
Hepatol Int; 2021 Aug; 15(4):892-900. PubMed ID: 34260013
[TBL] [Abstract][Full Text] [Related]
32. Risk of HCC in individuals of sub-Saharan ethnicity or descent with chronic hepatitis B in Europe.
Ray K
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):2. PubMed ID: 37990097
[No Abstract] [Full Text] [Related]
33. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
Fan R; Niu J; Ma H; Xie Q; Cheng J; Rao H; Dou X; Xie J; Zhao W; Peng J; Gao Z; Gao H; Chen X; Chen J; Li Q; Tang H; Zhang Z; Ren H; Cheng M; Liang X; Zhu C; Wei L; Jia J; Sun J; Hou J;
Aliment Pharmacol Ther; 2021 Aug; 54(3):329-338. PubMed ID: 34157146
[TBL] [Abstract][Full Text] [Related]
34. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
[TBL] [Abstract][Full Text] [Related]
35. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S; Tamaki N; Kaneko S; Kurosaki M; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Maeyashiki C; Yasui Y; Nakanishi H; Tsuchiya K; Itakura J; Takahashi Y; Izumi N
J Gastroenterol Hepatol; 2020 Sep; 35(9):1595-1601. PubMed ID: 31975419
[TBL] [Abstract][Full Text] [Related]
36. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
[TBL] [Abstract][Full Text] [Related]
37. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
38. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
39. Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation.
Campbell C; Wang T; Gillespie I; Barnes E; Matthews PC
Public Health; 2024 Jan; 226():215-227. PubMed ID: 38091810
[TBL] [Abstract][Full Text] [Related]
40. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
